文献速递泌尿男性生殖肿瘤

镭-223联合醋酸阿比特龙和泼尼松或泼尼松龙治疗去势抵抗性前列腺癌骨转移患者(ERA 223):一项随机、双盲、安慰剂对照、3期试验

Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial.
PubMed 文献 · Lancet Oncol · 2019-02-06

在19个国家165个中心开展的随机双盲安慰剂对照3期试验中,806例化疗初治的无症状或轻度症状去势抵抗性前列腺癌骨转移患者接受镭-223或安慰剂联合醋酸阿比特龙和泼尼松/泼尼松龙。镭-223组中位症状性骨骼事件无生存期22.3个月,安慰剂组26.0个月(HR 1.122,95%CI 0.917-1.374;p=0.2636),未改善主要终点,且骨折发生率更高(29% vs 11%),作者不推荐该联合方案。

要点

  • 镭-223联合阿比特龙未改善症状性骨骼事件无生存期(HR 1.122,p=0.2636)。
  • 镭-223组骨折发生率29%,安慰剂组11%。
  • 作者不推荐镭-223联合醋酸阿比特龙和泼尼松/泼尼松龙。

核心结论

  • 在去势抵抗性前列腺癌骨转移患者中,镭-223联合醋酸阿比特龙和泼尼松或泼尼松龙未改善症状性骨骼事件无生存期,且骨折频率增加,作者不推荐该联合方案。

研究设计与样本

  • 随机、双盲、安慰剂对照、3期试验,在19个国家165个肿瘤和泌尿中心开展。
  • 纳入806例组织学确诊的进展性、化疗初治、无症状或轻度症状的去势抵抗性前列腺癌骨转移患者,ECOG体能状态0或1,预期寿命至少6个月。
  • 患者按1:1随机分配接受最多6次静脉注射镭-223(55 kBq/kg)或匹配安慰剂,每4周一次,同时口服醋酸阿比特龙1000 mg每日一次加泼尼松或泼尼松龙5 mg每日两次。
  • 主要终点为症状性骨骼事件无生存期,在意向治疗人群中评估;安全性分析纳入至少接受一剂研究药物的所有患者。

主要发现

  • 至主要分析数据截止(2018年2月15日),镭-223组401例中196例(49%)发生至少一次症状性骨骼事件或死亡,安慰剂组405例中190例(47%)(中位随访21.2个月,IQR 17.0-25.8)。
  • 中位症状性骨骼事件无生存期:镭-223组22.3个月(95%CI 20.4-24.8),安慰剂组26.0个月(95%CI 21.8-28.3),HR 1.122(95%CI 0.917-1.374),p=0.2636。
  • 任何级别骨折:镭-223组392例中112例(29%),安慰剂组394例中45例(11%)。
  • 最常见的3-4级治疗中出现的不良事件:高血压镭-223组43例(11%)vs 安慰剂组52例(13%),骨折36例(9%)vs 12例(3%),丙氨酸氨基转移酶升高34例(9%)vs 28例(7%)。
  • 严重治疗中出现的不良事件:镭-223组160例(41%),安慰剂组155例(39%);治疗相关死亡:镭-223组2例(1%)(急性心肌梗死和间质性肺病),安慰剂组1例(<1%)(心律失常)。

临床怎么用

  • 作者结论为不推荐使用镭-223联合醋酸阿比特龙和泼尼松或泼尼松龙。

局限性

  • 研究因镭-223组骨折和死亡多于安慰剂组(非计划事后分析)而于2017年11月17日提前揭盲,但所有患者在此日期前已完成镭-223或安慰剂治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Abiraterone acetate plus prednisone or prednisolone improves progression-free survival and overall survival in patients with metastatic castration-resistant prostate cancer. Radium-223 improves overall survival and delays the onset of symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases. We assessed concurrent treatment with abiraterone acetate plus prednisone or prednisolone and radium-223 in such patients. METHODS: We did a randomised, double-blind, placebo-controlled, phase 3 trial at 165 oncology and urology centres in 19 countries. Eligible patients were aged 18 years or older, and had histologically confirmed, progressive, chemotherapy-naive, asymptomatic or mildly symptomatic castration-resistant prostate cancer and bone metastases, Eastern Cooperative Oncology Group performance status of 0 or 1, life expectancy of at least 6 months, and adequate haematological, renal, and liver function. Participants were randomly assigned (1:1) according to a permuted block design (block size 4) via interactive response technology to receive up to six intravenous injections of radium-223 (55 kBq/kg) or matching placebo once every 4 weeks. All patients were also scheduled to receive oral abiraterone acetate 1000 mg once daily plus oral prednisone or prednisolone 5 mg twice daily during and after radium-223 or placebo treatment. The primary endpoint was symptomatic skeletal event-free survival, which was assessed in the intention-to-treat population. Safety analyses were done in all patients who received at least one dose of any study drug. This trial is registered with ClinicalTrials.gov, number NCT02043678. Enrolment has been completed, and follow-up is ongoing. FINDINGS: Between March 30, 2014, and Aug 12, 2016, 806 patients were randomly assigned to receive radium-223 (n=401) or placebo (n=405) in addition to abiraterone acetate plus prednisone or prednisolone. The study was unblinded prematurely, on Nov 17, 2017, after more fractures and deaths were noted in the radium-223 group than in the placebo group (in an unplanned ad-hoc analysis), but all patients had completed radium-223 or placebo before this date. At the primary analysis (data cutoff Feb 15, 2018), 196 (49%) of 401 patients in radium-223 group had had at least one symptomatic skeletal event or died, compared with 190 (47%) of 405 patients in the placebo group (median follow-up 21·2 months [IQR 17·0-25·8]). Median symptomatic skeletal event-free survival was 22·3 months (95% CI 20·4-24·8) in the radium-223 group and 26·0 months (21·8-28·3) in the placebo group (hazard ratio 1·122 [95% CI 0·917-1·374]; p=0·2636). Fractures (any grade) occurred in 112 (29%) of 392 patients in the radium-223 group and 45 (11%) of 394 patients in the placebo group. The most common grade 3-4 treatment-emergent adverse events were hypertension (43 [11%] patients in the radium-223 group vs 52 [13%] patients in the placebo group), fractures (36 [9%] vs 12 [3%]) and increased alanine aminotransferase concentrations (34 [9%] vs 28 [7%]). Serious treatment-emergent adverse events occurred in 160 (41%) patients in the radium-223 group and 155 (39%) in the placebo group. Treatment-related deaths occurred in two (1%) patients in the radium-223 group (acute myocardial infarction and interstitial lung disease) and one (<1%) in the placebo group (arrhythmia). INTERPRETATION: The addition of radium-223 to abiraterone acetate plus prednisone or prednisolone did not improve symptomatic skeletal event-free survival in patients with castration-resistant prostate cancer and bone metastases, and was associated with an increased frequency of bone fractures compared with placebo. Thus, we do not recommend use of this combination. FUNDING: Bayer.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Smith M, Parker C, Saad F, et al. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019. PMID: 30738780. doi:10.1016/S1470-2045(18)30860-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。